Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Red clover isoflavones** are a variable botanical dietary-supplement preparation derived from *Trifolium pratense*. The principal phytoestrogenic constituents are typically biochanin A and formononetin, with smaller and variable amounts of genistein, daidzein, and related isoflavones. These constituents and their metabolites can interact with estrogen receptors, producing weak and tissue-dependent estrogenic activity. In a randomized double-blind crossover study, approximately 50 mg/day of red clover isoflavones for four weeks lowered daytime ambulatory blood pressure and improved an indirect measure of basal endothelial nitric oxide activity in postmenopausal women with type 2 diabetes. This is a nutraceutical mixture rather than a single standardized pharmaceutical active ingredient; composition, dose, bioavailability, and clinical effects vary across products.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on red clover isoflavones.